Rentokil Initial experienced a sharp sell-off, with its shares falling 18.4% to 361.7p after the company published H1 2026 interim results before the London market opened. The decline was driven by a marked deceleration in North American Pest Control Services organic revenue growth - a closely watched indicator investors have used to gauge the sustainability of the region's recovery.
The report showed North American pest control organic growth eased to 2.4% in Q2, down from 2.8% in Q1. Within that region, commercial revenues were pressured by weaker performance in National Accounts and a slowdown in Termite revenues. These developments disappointed a market that had been anticipating continued acceleration after momentum seen in late 2025.
On headline financials, the results were stronger than many analysts expected. Group revenue rose 6.7% to $3.59 billion and adjusted profit before tax came in at $459 million, ahead of the roughly $443 million analysts had been forecasting. Free cash flow conversion also registered at a robust 96%.
Despite the profit upside, the contrast between the earnings beat and the softer organic growth highlighted that the North American turnaround is advancing more slowly than investors had hoped. The company's interim statement described the period as one of "building the platform" for future growth rather than asserting that the recovery is complete.
Market context did little to cushion the move. Major U.S. equity indices were mildly positive on the day - the S&P 500 rose 0.4% and the Nasdaq gained 0.7% - indicating Rentokil's drop was driven by company-specific results and commentary rather than broader equity weakness.
Peers in the global facilities services and pest control space did not report comparable negative developments, which accentuated Rentokil's underperformance within the FTSE 100. The share price had already been under pressure over the past year; the latest sell-off pushed the stock nearer to its 52-week low of 349.7p.
Investors reacted to a combination of factors: slowing residential Termite demand, softer commercial National Account revenues, and conservative forward language from management. The mix produced a sell-the-news response that wiped out nearly a fifth of the company's market value in a single trading session.
In short, while the headline numbers demonstrated underlying profitability and strong cash conversion, the investor focus on North American organic growth - and its slowing trajectory - dominated market sentiment. Management's characterization of the period as preparatory rather than evidentiary of a complete recovery left some investors unconvinced that the North American platform is ready to deliver the acceleration many had been expecting.
What to watch next
- Quarterly organic growth trends in North America, particularly Termite and National Accounts performance.
- Management commentary around the pace of recovery and execution against the platform-building objectives.
- Comparative results from peers in facilities services and pest control to assess whether Rentokil's trajectory is company-specific.